Remission Induction and Sustenance in Graves' Disease 2
Graves Disease, Hyperthyroidism
About this trial
This is an interventional prevention trial for Graves Disease
Eligibility Criteria
Inclusion Criteria:
- Graves hyperthyroidism in remission after ATD
Exclusion Criteria:
- Age < 18, severe concomitant disease
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
No Intervention
Experimental
Stop of medication after remission
Medication for 2 yrs after remission
Se-yeast 200 Microgr/day + arm A
After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in: Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.